Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia.

Batcha AMN, Bamopoulos SA, Kerbs P, Kumar A, Jurinovic V, Rothenberg-Thurley M, Ksienzyk B, Philippou-Massier J, Krebs S, Blum H, Schneider S, Konstandin N, Bohlander SK, Heckman C, Kontro M, Hiddemann W, Spiekermann K, Braess J, Metzeler KH, Greif PA, Mansmann U, Herold T.

Sci Rep. 2019 Aug 13;9(1):11796. doi: 10.1038/s41598-019-48167-4.

2.

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.

Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA.

Haematologica. 2019 Jul 11. pii: haematol.2018.214882. doi: 10.3324/haematol.2018.214882. [Epub ahead of print]

3.

Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.

Karjalainen R, Liu M, Kumar A, He L, Malani D, Parsons A, Kontro M, Kallioniemi O, Porkka K, Heckman CA.

Leukemia. 2019 Jun 7. doi: 10.1038/s41375-019-0504-y. [Epub ahead of print] No abstract available.

PMID:
31175323
4.

8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia.

Buettner R, Nguyen LXT, Kumar B, Morales C, Liu C, Chen LS, Pemovska T, Synold TW, Palmer J, Thompson R, Li L, Hoang DH, Zhang B, Ghoda L, Kowolik C, Kontro M, Leitch C, Wennerberg K, Yu X, Chen CC, Horne D, Gandhi V, Pullarkat V, Marcucci G, Rosen ST.

J Cell Physiol. 2019 Feb 15. doi: 10.1002/jcp.28294. [Epub ahead of print]

PMID:
30770553
5.

Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.

Kivioja JL, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder MM, Javarappa KK, Eldfors S, Schwaller J, Porkka K, Heckman CA.

Leukemia. 2019 Jun;33(6):1360-1372. doi: 10.1038/s41375-018-0327-2. Epub 2018 Dec 19.

PMID:
30568173
6.

Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia.

Ojamies PN, Kontro M, Edgren H, Ellonen P, Heckman C, Porkka K, Wolf M, Kallioniemi O.

Leuk Lymphoma. 2018 Dec;59(12):3002-3005. doi: 10.1080/10428194.2018.1453067. Epub 2018 Apr 4. No abstract available.

PMID:
29616861
7.

Influence of organic matter, nutrients, and cyclodextrin on microbial and chemical herbicide and degradate dissipation in subsurface sediment slurries.

Kerminen K, Le Moël R, Harju V, Kontro MH.

Sci Total Environ. 2018 Mar 15;618:1449-1458. doi: 10.1016/j.scitotenv.2017.09.302. Epub 2017 Oct 18.

PMID:
29054658
8.

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.

Laukkanen S, Grönroos T, Pölönen P, Kuusanmäki H, Mehtonen J, Cloos J, Ossenkoppele G, Gjertsen B, Øystein B, Heckman C, Heinäniemi M, Kontro M, Lohi O.

Blood Cancer J. 2017 Sep 8;7(9):e604. doi: 10.1038/bcj.2017.87. No abstract available.

9.

Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia.

Kivioja JL, Lopez Martí JM, Kumar A, Kontro M, Edgren H, Parsons A, Lundán T, Wolf M, Porkka K, Heckman CA.

Leuk Lymphoma. 2018 Mar;59(3):725-732. doi: 10.1080/10428194.2017.1357174. Epub 2017 Aug 4.

PMID:
28776436
10.

A zero-valent iron and organic matter mixture enhances herbicide and herbicide degradation product removal in subsurface waters.

Kerminen K, Salovaara V, Kontro MH.

J Environ Sci (China). 2017 Jul;57:411-417. doi: 10.1016/j.jes.2016.12.013. Epub 2016 Dec 29.

PMID:
28647263
11.

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.

Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M, Porkka K, Aittokallio T, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA.

Blood. 2017 Aug 10;130(6):789-802. doi: 10.1182/blood-2016-02-699363. Epub 2017 Jun 15.

12.

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.

Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K.

Oncotarget. 2017 Apr 4;8(14):22606-22615. doi: 10.18632/oncotarget.15146.

13.

Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry.

Heikkinen T, Kämpjärvi K, Keskitalo S, von Nandelstadh P, Liu X, Rantanen V, Pitkänen E, Kinnunen M, Kuusanmäki H, Kontro M, Turunen M, Mäkinen N, Taipale J, Heckman C, Lehti K, Mustjoki S, Varjosalo M, Vahteristo P.

Hum Mutat. 2017 Mar;38(3):269-274. doi: 10.1002/humu.23157. Epub 2017 Jan 11.

PMID:
28054750
14.

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.

Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, Kumar A, Karjalainen R, Majumder MM, Ojamies P, Pemovska T, Wennerberg K, Heckman C, Porkka K, Wolf M, Aittokallio T, Kallioniemi O.

Leukemia. 2017 May;31(5):1187-1195. doi: 10.1038/leu.2016.314. Epub 2016 Nov 11.

15.

Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.

Ojamies PN, Kontro M, Edgren H, Ellonen P, Lagström S, Almusa H, Miettinen T, Eldfors S, Tamborero D, Wennerberg K, Heckman C, Porkka K, Wolf M, Kallioniemi O.

Leukemia. 2017 May;31(5):1048-1058. doi: 10.1038/leu.2016.286. Epub 2016 Oct 31.

PMID:
27795554
16.

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.

Kontro M, Kumar A, Majumder MM, Eldfors S, Parsons A, Pemovska T, Saarela J, Yadav B, Malani D, Fløisand Y, Höglund M, Remes K, Gjertsen BT, Kallioniemi O, Wennerberg K, Heckman CA, Porkka K.

Leukemia. 2017 Feb;31(2):301-309. doi: 10.1038/leu.2016.222. Epub 2016 Aug 8.

PMID:
27499136
17.

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.

Eldfors S, Kuusanmäki H, Kontro M, Majumder MM, Parsons A, Edgren H, Pemovska T, Kallioniemi O, Wennerberg K, Gökbuget N, Burmeister T, Porkka K, Heckman CA.

Leukemia. 2017 Jan;31(1):51-57. doi: 10.1038/leu.2016.202. Epub 2016 Jul 27.

18.

Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.

Kämpjärvi K, Kim NH, Keskitalo S, Clark AD, von Nandelstadh P, Turunen M, Heikkinen T, Park MJ, Mäkinen N, Kivinummi K, Lintula S, Hotakainen K, Nevanlinna H, Hokland P, Böhling T, Bützow R, Böhm J, Mecklin JP, Järvinen H, Kontro M, Visakorpi T, Taipale J, Varjosalo M, Boyer TG, Vahteristo P.

Prostate. 2016 Jan;76(1):22-31. doi: 10.1002/pros.23092. Epub 2015 Sep 18.

PMID:
26383637
19.

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.

Pietarinen PO, Pemovska T, Kontro M, Yadav B, Mpindi JP, Andersson EI, Majumder MM, Kuusanmäki H, Koskenvesa P, Kallioniemi O, Wennerberg K, Heckman CA, Mustjoki S, Porkka K.

Blood Cancer J. 2015 May 1;5:e309. doi: 10.1038/bcj.2015.30.

20.

Depth, soil type, water table, and site effects on microbial community composition in sediments of pesticide-contaminated aquifer.

Mattsson MK, Liu X, Yu D, Kontro MH.

Environ Sci Pollut Res Int. 2015 Jul;22(13):10263-79. doi: 10.1007/s11356-015-4224-1. Epub 2015 Feb 24.

PMID:
25703619
21.

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P, Cronin CN, McTigue M, Kallioniemi O, Porkka K, Murray BW, Wennerberg K.

Nature. 2015 Mar 5;519(7541):102-5. doi: 10.1038/nature14119. Epub 2015 Feb 9.

PMID:
25686603
22.

Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia.

Kämpjärvi K, Järvinen TM, Heikkinen T, Ruppert AS, Senter L, Hoag KW, Dufva O, Kontro M, Rassenti L, Hertlein E, Kipps TJ, Porkka K, Byrd JC, de la Chapelle A, Vahteristo P.

Oncotarget. 2015 Jan 30;6(3):1884-8.

23.

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.

Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, Majumder MM, Malani D, Murumägi A, Knowles J, Porkka K, Heckman C, Kallioniemi O, Wennerberg K, Aittokallio T.

Sci Rep. 2014 Jun 5;4:5193. doi: 10.1038/srep05193.

24.

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.

Kontro M, Kuusanmäki H, Eldfors S, Burmeister T, Andersson EI, Bruserud O, Brümmendorf TH, Edgren H, Gjertsen BT, Itälä-Remes M, Lagström S, Lohi O, Lundán T, Martí JM, Majumder MM, Parsons A, Pemovska T, Rajala H, Vettenranta K, Kallioniemi O, Mustjoki S, Porkka K, Heckman CA.

Leukemia. 2014 Aug;28(8):1738-42. doi: 10.1038/leu.2014.89. Epub 2014 Feb 27. No abstract available.

PMID:
24573384
25.

Dichlobenil and 2,6-dichlorobenzamide (BAM) dissipation in topsoil and deposits from groundwater environment within the boreal region in southern Finland.

Pukkila V, Kontro MH.

Environ Sci Pollut Res Int. 2014 Feb;21(3):2289-2297. doi: 10.1007/s11356-013-2164-1. Epub 2013 Sep 21.

PMID:
24057965
26.

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K.

Cancer Discov. 2013 Dec;3(12):1416-29. doi: 10.1158/2159-8290.CD-13-0350. Epub 2013 Sep 20.

27.

Evolution of clostridia and streptomycetes in full-scale composting facilities and pilot drums equipped with on-line temperature monitoring and aeration.

Rainisalo A, Romantschuk M, Kontro MH.

Bioresour Technol. 2011 Sep;102(17):7975-83. doi: 10.1016/j.biortech.2011.05.087. Epub 2011 Jun 12.

PMID:
21719280
28.

Wood ash for application in municipal biowaste composting.

Kurola JM, Arnold M, Kontro MH, Talves M, Romantschuk M.

Bioresour Technol. 2011 Apr;102(8):5214-20. doi: 10.1016/j.biortech.2011.01.092. Epub 2011 Feb 24.

PMID:
21349704
29.

Effect of light Sphagnum peat on odour formation in the early stages of biowaste composting.

Kurola JM, Arnold M, Kontro MH, Talves M, Romantschuk M.

Waste Manag. 2010 May;30(5):779-86. doi: 10.1016/j.wasman.2009.12.014. Epub 2010 Jan 12.

PMID:
20061130
30.

Determination of fungal succession during municipal solid waste composting using a cloning-based analysis.

Hultman J, Vasara T, Partanen P, Kurola J, Kontro MH, Paulin L, Auvinen P, Romantschuk M.

J Appl Microbiol. 2010 Feb;108(2):472-87. doi: 10.1111/j.1365-2672.2009.04439.x. Epub 2009 Jun 25.

31.

The most-probable-number enumeration of dichlobenil and 2,6-dichlorobenzamide (BAM) degrading microbes in Finnish aquifers.

Pukkila V, Gustafsson J, Tuominen J, Aallonen A, Kontro MH.

Biodegradation. 2009 Sep;20(5):679-86. doi: 10.1007/s10532-009-9255-1. Epub 2009 Mar 27.

PMID:
19326247
32.

Silylation can be omitted in gas-liquid chromatographic/mass spectrometric analysis of ergosterol.

Kontro MH, Vauramo S.

Rapid Commun Mass Spectrom. 2009 Mar;23(5):722-4. doi: 10.1002/rcm.3893. No abstract available.

PMID:
19191255
33.

Atrazine and terbutryn degradation in deposits from groundwater environment within the boreal region in Lahti, Finland.

Talja KM, Kaukonen S, Kilpi-Koski J, Malin I, Kairesalo T, Romantschuk M, Tuominen J, Kontro MH.

J Agric Food Chem. 2008 Dec 24;56(24):11962-8. doi: 10.1021/jf802528a.

PMID:
19053391
34.

Selected ion monitoring in quantitative gas-liquid chromatographic-mass spectrometric detection of fatty acid methyl esters from environmental samples.

Kontro M, Korhonen L, Vartiainen T, Pellikka P, Martikainen PJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):281-7. Epub 2005 Dec 27.

PMID:
16384750
35.

pH effects on 10 Streptomyces spp. growth and sporulation depend on nutrients.

Kontro M, Lignell U, Hirvonen MR, Nevalainen A.

Lett Appl Microbiol. 2005;41(1):32-8.

36.

Occurrence of nitrifiers and diversity of ammonia-oxidizing bacteria in developing drinking water biofilms.

Lipponen MT, Martikainen PJ, Vasara RE, Servomaa K, Zacheus O, Kontro MH.

Water Res. 2004 Dec;38(20):4424-34.

PMID:
15556217
37.

Microbial community structure and biomass in developing drinking water biofilms.

Keinänen MM, Martikainen PJ, Kontro MH.

Can J Microbiol. 2004 Mar;50(3):183-91.

PMID:
15105885
38.

Gas-chromatographic lipid profiles in identification of currently known slowly growing environmental mycobacteria.

Torkko P, Katila ML, Kontro M.

J Med Microbiol. 2003 Apr;52(Pt 4):315-23.

PMID:
12676870
39.

Gas chromatographic-mass spectrometric detection of 2- and 3-hydroxy fatty acids as methyl esters from soil, sediment and biofilm.

Keinänen MM, Korhonen LK, Martikainen PJ, Vartiainen T, Miettinen IT, Lehtola MJ, Nenonen K, Pajunen H, Kontro MH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 15;783(2):443-51.

PMID:
12482487

Supplemental Content

Loading ...
Support Center